TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05634070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCL Pectus scaffold implantation and autologous fat grafting
Description: A suitable incision will be made using a scalpel and diathermy following standard surgical procedures.The implant pocket shall be rinsed with saline. The PCL Pectus Scaffold shall be inserted into the pocket following the Instruction for Use and fixed to the thoracic wall using 2 to 4 sutures. The device shall not be modified for any patient in any manner. The incision shall be closed using 2-0 Vicryl or Monocryl and 3-0 Monocryl sutures, if applicable. Number of layers to be sutured will be decided by the PI for each patient. Sterile bandaging as well as Steri-Strips shall be applied on the sutures. A prophylactic antibiotic such as Cefazolin 1g (3 shots per day x 2 days) shall be administered to the patient. In case the patient has Cefazolin allergy, Clindamycin 600 mg shall be prescribed. Autologous Fat Grafting procedure shall be performed immediately after implantation. The patients shall be hospitalized for the necessary number of days under clinical observation.
Study: NCT05227365

Intervention type: DEVICE
Group type: OTHER
Intervention: Lenire
Description: The sound stimulus of PS6 is comprised of sequences of tones and is spectrally modified according to the participant's hearing thresholds so that different components of the sound stimulus can be sufficiently heard by the participant irrespective of their hearing characteristics (audiological profile). The tongue stimulus of PS6 is delivered by an array of electrical signals via 32 transmucosal electrodes contacting the anterodorsal surface of the tongue. The sound and tongue stimulus parameters are presented with certain stimulus rates and timing relationships between modalities.
Study: NCT04712643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until participant experience loss of clinical benefit as evaluated by the investigator or unacceptable toxicity or withdrawal of informed consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Becavizumab
Description: Bevacizumab will be administered by IV infusion at a fixed dose of 15 mg/kg on Day 1 of each 21-day Cycle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization (TACE)
Description: TACE will be performed by clinical demand.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial chemoembolization (TACE)
Description: TACE will be performed by clinical demand.
Study: NCT05378958

Intervention type: OTHER
Intervention: Individual interview
Description: Individual semi-directed explication interview with phenomenological questioning centered on lived experience.~The individual interview aims to collect data by questioning the participants using interview communication techniques, essentially on the reformulation technique. The interview is structured using an interview guide containing the list of open questions with prompts to be answered during the discussion.

Intervention type: OTHER
Intervention: Individual interview
Description: Individual semi-directed explication interview with phenomenological questioning centered on lived experience.~The individual interview aims to collect data by questioning the participants using interview communication techniques, essentially on the reformulation technique. The interview is structured using an interview guide containing the list of open questions with prompts to be answered during the discussion.
Study: NCT05327569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Chain Release Techniques
Description: Myofascial release technique will be applied to the center of coordination points in the anterior superficial myofascial chain of the body. There are a total of 8 points on this myofascial chain. Pressure will be applied to each point with 6 repetitions and lasting approximately 5-6 seconds.
Study: NCT05287932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief physical activity intervention
Description: See arm/group descriptions
Study: NCT05441280

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pimavanserin
Description: pimavanserin 34mg PO at bedtime

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a pill that looks like a study medication but has no medication in it
Study: NCT06278662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video directly observed therapy (vDOT)
Description: The first intervention of within the CIRCUS study is video directly observed therapy (vDOT). The intervention consists of taking recording of daily inhalation use and receiving four feedback sessions of an asthma nurse based on these home recordings.
Study: NCT05581030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy)
Description: Hyper-CVAD consists of two combinations of drugs (courses A and B) given in an alternating fashion. The term hyper refers to the hyperfractionated nature of the chemotherapy, which is given in small doses, more frequently, to minimize side effects. CVAD is the acronym of the drugs in course a: cyclophosphamide, vincristine, doxorubicin and dexamethasone.~Course A: Cyclophosphamide days 1, 2 and 3. Vincristine days 4 and 11, Doxorubicin day 4, dexamethasone days 1-4 and 11-14, Cytarabine day 7. Mesna is also given orally with cyclophosphamide, to reduce the incidence of haemorrhagic cystitis, a common side effect of cyclophosphamide. Methotrexate, an antimetabolite, may be given when necessary to get chemotherapy past the blood brain barrier.~Course B: Methotrexate Day 1 and Cytarabine Days 2 and 3. Dosage is individualized to the patient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase Pegol
Description: Calaspargase pegol 2000 IU/m\^2 (capped at 3750 IU) will be administered beginning in cycle 1B of Hyper-CVAD, and will continue at this dose for the duration of the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375mg/m\^2 will be administered once per cycle for patients with CD20+ ALL.
Study: NCT04069572

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrotactile Stimulation
Description: Application of VCR stimulation to the belly and back of patients with pelvic pain, functional abdominal pain, or low back pain or to the temporal region for patients with migraine.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Low-frequency sham of VCR stimulation
Study: NCT05608252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS-6766
Description: Taken Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS-6766
Description: Taken Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Taken Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Taken Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Administered by intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Administered by intramuscular injection
Study: NCT06102304

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Extracorpeal Shock wave
Description: Focused Extracorporeal shock wave for 700 impulses of 0.056 mJ/mm at a frequency of 10 Hz to the taut band and 300 impulses surrounding the taut band was applied as low energy 2 sessions per week for 4 weeks. (EME S.r.l. via Degli Abeti 88/161122 Pesaro \[serial number: EM12681015\], Italy) was used as a focused extracorporeal shock wave therapy apparatus.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Extracorpeal shock wave
Description: (EME S.r.l. via Degli Abeti 88/161122 Pesaro \[serial number: EM12681015\], Italy) was used as a focused extracorporeal shock wave therapy apparatus. The device will be used in the demo mood with no radiation or impulses applied.
Study: NCT06470867

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VA S.A.V.E.
Description: The intervention is called VA S.A.V.E. It is an online video-based training tailored to veterans and their close supports. It is free, brief (24 minutes), and includes three scripted role plays.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control training
Description: An attention control informational video containing information relevant to veterans' mental health but not including elements thought to be active ingredients in the intervention.
Study: NCT06235879

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group (Interscalene brachial plexus block)
Description: Patients will receive ultrasound guided interscalene brachial plexus block after induction of general anesthesia.~Scanning with SonoSite M-Turbo C ® Ultrasound device with HFL - 38 X Linear probe (Japan) with high frequency (6 -13 MHz) will be started just below the level of the cricoid cartilage medial to the sternocleidomastoid muscle.~the transducer will be moved slightly laterally across the neck to identify the scalene muscles and the brachial plexus that is present between the anterior and middle scalene muscles at the level of the sixth cervical vertebra deep to the sternocleidomastoid muscle.~The needle will be then inserted in-plane toward the brachial plexus, in a lateral-to-medial direction.~After negative aspiration and assurance that high resistance to injection is absent, 0.25% bupivacaine hydrochloride will be injected in a 5-ml increment below the lower root, between the 3 roots, and above the upper root.(Total amount is 15 ml of 0.25% bupivacaine hydrochloride).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericapsular nerve group (PENG) block
Description: Patients will receive ultrasound guided Pericapsular nerve group (PENG) block after induction of general anesthesia.~Using SonoSite M-Turbo C ® Ultrasound device with HFL - 38 X Linear probe (Japan) with high frequency (6 -13 MHz) ,A linear ultrasound probe will be placed longitudinally between the coracoid and the humeral head.~After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle over it, a 50-mm needle will be inserted using the ''in plane'' technique. When the needle pass through the deltoid muscle and touched the subscapularis tendon, a bone-like hard tissue will be felt and the needle can't be advanced further.~The needle tip will be placed between the deltoid muscle and subscapularis tendon, after a careful aspiration, 15 ml of 0.25% bupivacaine hydrochloride will be injected.
Study: NCT04882462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab, 400mg, intravenously every 3 weeks, for at least 18 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab, 200mg, intravenously every 3 weeks, for at least 18 weeks;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy drug
Description: Chemotherapy drugs were selected by the investigator, every 3 weeks, for 18 weeks
Study: NCT02981134

Intervention type: PROCEDURE
Intervention: Computed tomographic scan
Description: after 1year of BVS implantation, computed tomographic scan will be performed
Study: NCT05971641

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: progressive relaxation exercise
Description: Patients who undergo total knee replacement surgery in the experimental group will be taught progressive relaxation exercises. The exercise will last for 30 minutes and will be applied twice a day. Patients will wear a smart wristband. Patient Information Form, Numeric Rating Scale, Richard Campbell Sleep Quality Survey, and Postoperative Recovery Index Scale will be administered. The scales will be filled out for 5 days and will take approximately 10-15 minutes.
Study: NCT04880213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5049
Description: Participants will receive single oral dose of film-coated tablet M5049 at low dose on Day 1 under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5049
Description: Participants will receive single oral dose of film-coated tablet M5049 at low dose on Day 1 under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5049
Description: Participants will receive single oral dose of film-coated tablet M5049 at medium dose on Day 1 under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5049
Description: Participants will receive single oral dose of film-coated tablet M5049 at medium dose on Day 1 under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5049
Description: Participants will receive single oral dose of film-coated tablet M5049 at high dose on Day 1 under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5049
Description: Participants will receive single oral dose of film-coated tablet M5049 at high dose on Day 1 under fasted condition.
Study: NCT04864561

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLA2001
Description: whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxide 2 vaccinations 28 days apart

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AZD1222
Description: 2 vaccinations 28 days apart AZD1222 is a recombinant, replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 S surface glycoprotein.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLA2001 - adolescent part
Description: whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxid 2 vaccinations 28 days apart and with a booster vaccination on day 208. Placebo group will receive VLA2001 on day 208 and following second vaccination 28 days later.
Study: NCT04963231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: SC injection
Study: NCT04864561

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 vaccinations 28 days apart with placebo (PBS buffer based on Dulbecco's PBS media formulation without Calcium and Magnesium )
Study: NCT06398899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group S: sugammadex injection
Description: Reversal agent: sugammadex no TOF (train-of-four) response, Sugammadex 4 mg/kg TOF count is ≥ 1, Sugammadex 2 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group N: neostigmine/glycopyrrolate
Description: Reversal agent: glycopyrrolate and neostigmine. TOF 2-3, neostigmine 50 µg/kg; TOF 4, neostigmine 20-40 µg/kg For all patients, glycopyrrolate 0.4 mg is co-administered with neostigmine.
Study: NCT04963231

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injection
Study: NCT06440629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) of adalimumab
Description: In the TDM-group, the adalimumab dose will be adjusted according to the following algorithms in order to keep the drug level within the therapeutic range:~* Serum drug level within therapeutic range : keep dose~* Low drug levels, ADAb undetectable or low levels : Decrease dosing interval by one week to a maximum of 40 mg/week~* Low drug levels, ADAb high levels : Switch to another therapy~* High drug levels : Increase dosing interval by one week up to a maximum of 6 weeks
Study: NCT04957719

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Selatogrel
Description: Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. Selatogrel will be administered as a liquid formulation in a sealed prefilled syringe in an autoinjector forming an integral ready-to-use, single-dose drug delivery system.~Participants will self-administer 16 mg of selatogrel subcutaneously with the autoinjector upon occurrence of symptoms suggestive of an acute myocardial infarction. Self-administration encompasses the use of the autoinjector by another person (e.g., partner, close relative, friend, caregiver) who may be called for help during the emergency situation of a suspected AMI.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as a liquid formulation in a sealed prefilled syringe in an autoinjector forming an integral ready-to-use, single-dose drug delivery system.~Participants will self-administer placebo subcutaneously with the autoinjector upon occurrence of symptoms suggestive of an acute myocardial infarction. Self-administration encompasses the use of the autoinjector by another person (e.g., partner, close relative, friend, caregiver) who may be called for help during the emergency situation of a suspected AMI.
Study: NCT06387537

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: Patients in this group will recieve hot pack, ROM exercises, strengthening exercises and Kaltenborn mobilizations. A total of 12 sessions, 3 sessions per week for 4 consecutive weeks. Sets and repetitions will be increased progressively.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Description: Patients in this group will recieve hot pack, ROM exercises, strengthening exercises and Kaltenborn mobilizations. A total of 12 sessions, 3 sessions per week for 4 consecutive weeks. Sets and repetitions will be increased progressively.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scapular mobilization.
Description: Scapular Mobilizations: Glides- superior, inferior, distraction, upward and downward rotation (5 sets, 10 reps, 30 sec break in 1 session).Every session will be given for 30 minutes and a total of 12 sessions would be conducted over a period of 4 consecutive weeks.
Study: NCT06069648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: printed screening decision aid
Description: a booklet form of screening decision aid containing information of cervical cancer screening options

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: a leaftlet
Description: a leaflet containing information about healthy lifestyles

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile screening decision aid
Description: a mobile app format of screening decision aid containing information of cervical cancer screening options
Study: NCT05860933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3537982
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3537982
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Administered orally.
Study: NCT06580080

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Are You Ready? (AYR)
Description: AYR is a group-based entertainment education (EE) intervention designed for sexually active youth who are at risk for or involved in the juvenile justice and/or child welfare systems. AYR is delivered in one, 2.5-hour (150-minute) session with a group of between 2 to 20 youth. The session includes screening a 40-minute video, Happy Birthday, Leonard and group-based discussions led by one to two facilitators. Discussions are guided by a participant workbook with journal prompts and handouts.~The session includes two modules; each module involves screening approximately 20 minutes of Happy Birthday, Leonard followed by a 40-minute group discussion. Module 1 includes topics related to contraception, condom use (with a condom demonstration), healthy communication, and stress management. Module 2 includes topics related to condom negotiation, communication styles, and intergenerational cycles.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Social Media Awareness Shorts (SMAS)
Description: SMAS is a virtually delivered, individual-based health program focused on social media use awareness. Participants are directed to a learning management platform that contains a pre-recorded, facilitated program. The program involves watching several short films and independently completing several activities related to social media use. The program does not include information related to the primary outcomes for this study.
Study: NCT05510401

Intervention type: OTHER
Group type: OTHER
Intervention: SECURIDRAP® SELFIA®
Description: Use of SECURIDRAP® SELFIA® for 15 night
Study: NCT05907291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRN04894
Description: CRN04894 is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist.
Study: NCT06045806

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: idecabtagene vicleucel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Specified dose on specified days
Study: NCT06565715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Remimazolam is used for sedation during anesthetic induction and maintenance.

Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Description: propofol is used for sedation during anesthetic induction and maintenance.
Study: NCT06554964

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: performing chromotubation during the laparoscopy in order to assess the tubal patency of the remaining fallopian tube
Description: Performing chromotubation )injection of blue dye to the fallopian tube via cevical catheter) during the laparoscopy in order to assess the tubal patency of the remaining fallopian tube
Study: NCT04533217

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vertebroplasty
Description: Injection of cement into vertebral lesion(s)